The SEC filings page for OnKure Therapeutics, Inc. (OKUR) provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the Nasdaq Global Market. These documents offer detailed information about its precision oncology programs, financial condition, and capital markets activities, complementing the high-level descriptions found in press releases.
Through its periodic reports on Forms 10-K and 10-Q, OnKure describes its focus on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by current therapies. These filings expand on the company’s strategy around PI3Kα-targeted programs, including its lead candidate OKI-219 and its PI3Kα pan-mutant and other discovery-stage efforts, and include sections such as “Risk Factors” that outline scientific, clinical, regulatory, and financial risks.
Current reports on Form 8-K capture material events between periodic filings. For example, OnKure has filed 8-Ks to report quarterly financial results and to disclose entry into a sales agreement with Leerink Partners LLC for an at-the-market offering program of its Class A common stock. That agreement allows the company, subject to specified parameters and an effective shelf registration statement on Form S-3, to sell shares through Leerink Partners acting as sales agent, with compensation based on a percentage of gross proceeds.
On this page, users can review new and historical SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and registration statements such as Form S-3 referenced in the at-the-market program. Stock Titan’s tools apply AI-powered summaries to help explain the contents of lengthy filings, highlight key items like clinical development updates, capital raising arrangements, and risk disclosures, and make it easier to track how OnKure’s regulatory narrative evolves over time.
OnKure Therapeutics, Inc. (OKUR) is the subject of a Schedule 13G in which five reporting persons each report beneficial ownership of 2,700,000 shares of Class A common stock, or 6.67%. The reporting persons are Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry.
Coastlands Capital Partners LP holds the shares directly. Each reporting person reports shared voting and dispositive power over the shares, with zero sole voting or dispositive power. They filed jointly but each disclaims group membership and beneficial ownership except to the extent of that person's pecuniary interest. The calculation uses 40,496,309 shares outstanding as of August 3, 2026 and excludes pre-funded warrants held by the reporting persons in excess of a 4.99% beneficial ownership limitation. The Partnership holds the shares for its investors and has the right to receive or direct dividends or sale proceeds.
OnKure Therapeutics, Inc. President and CEO and director Nicholas A. Saccomano reported an automatic sale of 87 shares of Class A Common Stock on September 21, 2026, to cover tax withholding obligations related to restricted stock unit vesting. The weighted-average sale price was $2.9742 per share, with trades from $2.95 to $3.06. Saccomano reported 11,160 shares following the transaction; certain of those securities are RSUs. No Rule 10b5-1 plan is reported.
OnKure Therapeutics, Inc. (OKUR) Chief Financial Officer Jason A. Leverone reported an automatic sale of 302 shares of Class A common stock on September 21, 2026, to cover tax withholding obligations tied to vesting of restricted stock units (RSUs). The weighted average sale price was $2.9742 per share, with trades ranging from $2.95 to $3.06. He directly held 18,500 shares after the transaction. No Rule 10b5-1 plan is reported.
OnKure Therapeutics, Inc. is the issuer of Class A common stock covered in this beneficial ownership report. Investment adviser ADAR1 Capital Management, LLC and its manager Daniel Schneeberger each report beneficial ownership of 2,238,684 shares of Class A common stock, representing 5.5% of the class based on 40,496,309 shares outstanding as of June 30, 2026. These shares include holdings by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and other separately managed accounts for which ADAR1 Capital Management acts as investment manager or sub-adviser.
ADAR1 Capital Management GP, LLC, as general partner of ADAR1 Partners, LP, reports beneficial ownership of 1,832,117 shares, or 4.5% of the class, and this amendment is identified as an exit filing solely for ADAR1 Capital Management GP, LLC as a 5% owner. All reporting persons disclose shared voting and dispositive power over their reported shares and no sole voting or dispositive power.
OnKure Therapeutics, Inc. received an updated ownership report from a group of affiliated investment entities led by Biotechnology Value Fund and Mark N. Lampert. As of June 30, 2026, the group beneficially owned 3,235,778 shares of Class A common stock, representing approximately 8.0% of the 40,395,480 shares outstanding as of May 4, 2026.
The BVF funds and a managed account also hold pre-funded warrants exercisable for 2,147,534 additional shares at an exercise price of $0.0001 per share, subject to a 4.9% beneficial ownership cap that currently prevents any exercise. Various BVF-related entities share voting and dispositive power over these positions, while formally disclaiming beneficial ownership where noted.
Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund and Ortav Yehudai report their beneficial ownership of OnKure Therapeutics, Inc. Class A Common Stock as of June 30, 2026. They collectively may be deemed to beneficially own 1,438,456 shares, representing 3.6% of the outstanding shares, all held directly by Trails Edge Biotechnology Master Fund. The percentage is based on 40,395,480 shares outstanding as of May 4, 2026. Each filer has sole voting and dispositive power over these shares and confirms ownership of 5 percent or less of the class.
OnKure Therapeutics, Inc. director Isaac Manke filed an amended ownership report reflecting a stock option holding rather than a transaction. The amendment states that a previously reported disposition and corresponding acquisition of an option to purchase 15,300 shares of Class A Common Stock in connection with an Option Repricing did not occur. The filing instead reports a stock option, exercisable at $18.20 per share, covering 15,300 underlying shares and expiring on October 3, 2034. According to the vesting schedule, 1/36 of the option vested on November 4, 2024 and 1/36 continues to vest monthly, contingent on continued service.
OnKure Therapeutics, Inc. approved an option repricing effective August 7, 2026, resetting the exercise price of certain underwater employee and consultant stock options granted before January 1, 2025 to $4.14 per share, the Class A common stock closing price on the effective date. The change covers approximately 1.7 million shares with prior exercise prices at or above $10.00, including sizeable grants held by the CEO, CMO, and CFO. Vesting schedules, terms, and share counts are unchanged, and a retention requirement of 18 months for senior management and one year for other participants applies; exercising before meeting this requirement triggers a premium exercise price equal to the original strike. The board states the structure is intended to refresh performance and retention incentives while avoiding additional stock dilution or cash compensation costs.
OnKure Therapeutics, Inc. reported that director Edward T. Mathers received a grant of 22,350 stock options on August 7, 2026. The options carry an exercise price of $4.14 per share and are exercisable for Class A Common Stock. All of the shares subject to the option vest on the earlier of June 4, 2027 or the day prior to the company's next annual meeting of stockholders, subject to his continued service, and expire on August 6, 2036. Following this grant, he holds 22,350 derivative securities of this type directly.
OnKure Therapeutics, Inc. reported that director Liam Ratcliffe received a grant of 22,350 stock options, each representing the right to buy one share of Class A Common Stock at an exercise price of $4.14 per share. All 22,350 options will vest on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Ratcliffe holds 22,350 derivative securities of this option award, which is scheduled to expire on August 6, 2036.